Title:A Snapshot of Selenium-enclosed Nanoparticles for the Management of Cancer
Volume: 30
Issue: 11
Author(s): Rohitas Deshmukh*, Rajesh Singh, Sandeep Sharma, Ashwini Kumar Mishra and Ranjit Kumar Harwansh
Affiliation:
- Institute of Pharmaceutical Research, GLA University, Mathura 281406, India
Keywords:
Cancer, doxorubicin, nanoparticles, selenium, apoptosis, chemotherapy.
Abstract: Among the primary causes of mortality in today's world is cancer. Many drugs are employed to
give lengthy and severe chemotherapy and radiation therapy, like nitrosoureas (Cisplatin, Oxaliplatin), Antimetabolites
(5-fluorouracil, Methotrexate), Topoisomerase inhibitors (Etoposide), Mitotic inhibitors (Doxorubicin);
such treatment is associated with significant adverse effects. Antitumor antibiotics have side effects similar
to chemotherapy and radiotherapy. Selenium (Se) is an essential trace element for humans and animals,
and additional Se supplementation is required, particularly for individuals deficient in Se. Due to its unique features
and high bioactivities, selenium nanoparticles (SeNPs), which act as a supplement to counter Se deficiency,
have recently gained worldwide attention. This study presented a safer and more economical way of preparing
stable SeNPs. The researcher has assessed the antiproliferative efficiency of SeNPs-based paclitaxel delivery
systems against tumor cells in vitro with relevant mechanistic visualization. SeNPs stabilized by Pluronic
F-127 were synthesized and studied. The significant properties and biological activities of PTX-loaded SeNPs
on cancer cells from the lungs, breasts, cervical, and colons. In one study, SeNPs were formulated using chitosan
(CTS) polymer and then incorporated into CTS/citrate gel, resulting in a SeNPs-loaded chitosan/citrate
complex; in another study, CTS was used in the synthesis of SeNPs and then situated into CTS/citrate gel, resulting
in Se loaded nanoparticles. These formulations were found to be more successful in cancer treatment.
